2026年10月30日，歌礼制药有限公司（股票代码：01672）在香港联交所发布翌日披露报表，披露已于当日于联交所场内回购30万股普通股，占公司已发行股本约0.0285%。本次回购每股价格在4.85港元至5.25港元之间，合计动用资金1,500,185港元（约150.02万港元）。上述回购股份尚未注销，后续将按相关程序进行注销。
本次回购完成后，歌礼制药-B已发行股本总数仍维持1,052,202,859股，库藏股数量为5,784,210股。公告显示，公司已于2026年6月29日通过股份回购授权，授权总量为106,137,084股。截至目前，公司在香港联交所或其他证券交易所合并累计回购股份5,495,000股，占授权通过当日已发行股本的约0.5177%。
公司确认，此次回购符合香港联合交易所有限公司证券上市规则及相关法律的规定。本次公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.